Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 19/20 | 1.00 |
| ▸ | MMP3 | P08254 | 19/20 | 1.00 |
| ▸ | MMP7 | P09237 | 15/20 | 1.00 |
| ▸ | MMP2 | P08253 | 11/20 | 1.00 |
| ▸ | MMP9 | P14780 | 10/20 | 1.00 |
| ▸ | MMP8 | P22894 | 8/20 | 1.00 |
| ▸ | MMP13 | P45452 | 13/20 | 0.74 |
| ▸ | MMP12 | P39900 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6968720 | 0.87 | MMP1 (0.78) | MMP1MMP3MMP7MMP2MMP9 | |
| SCHEMBL6982015 | 0.85 | MMP1 (1.00) | MMP1MMP3MMP7MMP2MMP9 | |
| SCHEMBL11889703 | 0.85 | MMP1 (1.00) | MMP1MMP3MMP7MMP2MMP9 | |
| SCHEMBL20817163 | 0.85 | MMP1 (1.00) | MMP1MMP3MMP7MMP2MMP9 | |
| SCHEMBL7351911 | 0.82 | MMP1 (1.00) | MMP1MMP3MMP7MMP2MMP9 | |
| SCHEMBL7763139 | 0.80 | MMP1 (0.98) | MMP1MMP3MMP7MMP2MMP9 | |
| SCHEMBL7077683 | 0.80 | MMP1 (1.00) | MMP1MMP3MMP7MMP2MMP9 | |
| SCHEMBL6770467 | 0.80 | MMP1 (0.94) | MMP1MMP3MMP7MMP2MMP9 | |
| SCHEMBL7343866 | 0.80 | MMP1 (0.80) | MMP1MMP3MMP7MMP2MMP9 | |
| SCHEMBL6981692 | 0.79 | MMP1 (1.00) | MMP1MMP3MMP7MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030186958-A1 | Heterocyclic metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2003-10-02 | — | — | US | disclosed |
| US-6545038-B1 | N-substituted 3-oxyaminocarbonyl-1,4-oxazonine or -thiazonine derivatives | THE PROCTER & GAMBLE COMPANY | 2003-04-08 | — | — | US | disclosed |
| EP-0925287-B1 | HETEROCYCLIC METALLOPROTEASE INHIBITORS | PROCTER & GAMBLE (US) | 2003-01-15 | — | — | EP | disclosed |
| US-6166005-A | Heterocyclic metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2000-12-26 | — | — | US | disclosed |
| EP-0925287-A1 | HETEROCYCLIC METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 1999-06-30 | — | — | EP | disclosed |
| WO-1998008827-A1 | HETEROCYCLIC METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 1998-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186958-A1 | Heterocyclic metalloprotease inhibitors | MMP9, ADAM17, ADAM9 | MMP1 11/4885MMP3 8/4885MMP7 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.